A research team from Beth Israel Deaconess Medical Center this month published two papers implicating a single microRNA, miR-22, in both breast and hematologic cancers, and suggested that its suppression may be an effective therapeutic strategy.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: caution urged in use of gene drives, and more.
NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.
PLOS Biology has asked researchers how they envision the future of genetics and genomics.
Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."
In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.